NCT04914520已完成1 期
A Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of VN-0200 After Intramuscular Injections in Japanese Healthy Adults and Elderly Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Number of Participants Reporting Treatment-emergent Adverse Events
研究概览
简要总结
This study will assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injections in Japanese healthy adults and elderly subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged ≥20 and ≤50 years (Step 1) or healthy elderly aged ≥65 and ≤80 years (at the time of informed consent)
- •Body mass index (BMI) is ≥18.0 and <30.0 kg/m^2 (at screening)
排除标准
- •Participants with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination
- •Having alcohol or drug dependence, etc.
结局指标
主要结局
Number of Participants Reporting Treatment-emergent Adverse Events
时间窗: From first administration through 28 days post second administration
Number of Participants Reporting Local and Systemic Adverse Events
时间窗: From first administration up to 14 days after second administration
Number of Participants Reporting Serious Adverse Events
时间窗: From date of informed consent up to approximately 3 months
次要结局
- Geometric Mean Fold Rise (GMFR) of Anti-RSV Specific Neutralizing Activity(Day 29 and Day 57 post-dose and at the time of discontinuation (whichever occurs first), up to approximately 2 months)
- Geometric Mean Titer (GMT) of Anti-VAGA-9001a IgG(Day 1 (pre-dose), Day 29 and Day 57 post-dose, and at the time of discontinuation (whichever occurs first), up to approximately 2 months)
- Geometric Mean Titer (GMT) of Anti-RSV IgG(Day 1 (pre-dose), Day 29 and Day 57 post-dose, and at the time of discontinuation (whichever occurs first), up to approximately 2 months)
- Number of IFN-γ spot-forming cells in PBMC Detected by ELISPOT(Day 1 (pre-dose), Day 29 and Day 57 post-dose, and at the time of discontinuation (whichever occurs first), up to approximately 2 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Dose Finding Study of VN-0200Respiratory Syncytial Virus InfectionsNCT05547087Daiichi Sankyo342
已完成
1 期
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and AboveInfluenza ImmunizationHealthy VolunteersNCT06361875Sanofi Pasteur, a Sanofi Company908
终止
1 期
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous LeukemiaAdvanced MDSALLAdvanced CMLAdvanced MPNsAMLNCT02795520OncoTherapy Science, Inc.32
已完成
1 期
Safety Study of VM202 to Treat Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT02039401Helixmith Co., Ltd.18
已完成
1 期
The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)CMTNCT05361031Helixmith Co., Ltd.12